메뉴 건너뛰기




Volumn 68, Issue 7, 2013, Pages 825-828

Allergen immunotherapy: A new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 13 ANTIBODY; NUCLEIC ACID; TUMOR NECROSIS FACTOR ANTIBODY;

EID: 84880285353     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12180     Document Type: Note
Times cited : (41)

References (21)
  • 2
    • 84876903600 scopus 로고    scopus 로고
    • Update on allergy immunotherapy: American academy of allergy, asthma and immunology/european academy of allergy and clinical immunology/ PRACTALL consensus report
    • doi: 10.1016/j.jaci.2013.01.049.
    • Burks AW, Calderõn MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American academy of allergy, asthma and immunology/european academy of allergy and clinical immunology/ PRACTALL consensus report. J Allergy Clin Immunol 2013. doi: 10.1016/j.jaci.2013.01.049.
    • (2013) J Allergy Clin Immunol
    • Burks, A.W.1    Calderõn, M.A.2    Casale, T.3    Cox, L.4    Demoly, P.5    Jutel, M.6
  • 3
    • 50249230114 scopus 로고
    • Prophylactic inoculation against hay fever
    • Noon L,. Prophylactic inoculation against hay fever. Lancet 1911; 1: 1572-1573.
    • (1911) Lancet , vol.1 , pp. 1572-1573
    • Noon, L.1
  • 4
    • 50249195230 scopus 로고
    • Further observations on the treatment of hay-fever by hypodermic inoculation of pollen vaccine
    • Freeman J,. Further observations on the treatment of hay-fever by hypodermic inoculation of pollen vaccine. Lancet 1911; 2: 814-817.
    • (1911) Lancet , vol.2 , pp. 814-817
    • Freeman, J.1
  • 5
    • 33846964159 scopus 로고    scopus 로고
    • Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce
    • Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62: 317-324.
    • (2007) Allergy , vol.62 , pp. 317-324
    • Canonica, G.W.1    Baena-Cagnani, C.E.2    Bousquet, J.3    Bousquet, P.J.4    Lockey, R.F.5    Malling, H.J.6
  • 6
    • 0031736285 scopus 로고    scopus 로고
    • Allergen immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper
    • Bousquet J, Lockey R, Malling HJ,. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562.
    • (1998) J Allergy Clin Immunol , vol.102 , pp. 558-562
    • Bousquet, J.1    Lockey, R.2    Malling, H.J.3
  • 7
    • 40549093007 scopus 로고    scopus 로고
    • Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
    • Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86): 8-160.
    • (2008) Allergy , vol.63 , Issue.SUPPL. 86 , pp. 8-160
    • Bousquet, J.1    Khaltaev, N.2    Cruz, A.A.3    Denburg, J.4    Fokkens, W.J.5    Togias, A.6
  • 8
    • 70449133821 scopus 로고    scopus 로고
    • The CONSORT statement checklist in allergen-specific immunotherapy: A GA2LEN paper
    • Bousquet PJ, Brozek J, Bachert C, Bieber T, Bonini S, Burney P, et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009; 64: 1737-1745.
    • (2009) Allergy , vol.64 , pp. 1737-1745
    • Bousquet, P.J.1    Brozek, J.2    Bachert, C.3    Bieber, T.4    Bonini, S.5    Burney, P.6
  • 9
    • 78650922803 scopus 로고    scopus 로고
    • The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: A Global Allergy and Asthma European Network (GA(2)LEN) article
    • Bousquet PJ, Calderõn MA, Demoly P, Larenas D, Passalacqua G, Bachert C, et al. The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol 2011; 127: 49-56.
    • (2011) J Allergy Clin Immunol , vol.127 , pp. 49-56
    • Bousquet, P.J.1    Calderõn, M.A.2    Demoly, P.3    Larenas, D.4    Passalacqua, G.5    Bachert, C.6
  • 11
  • 12
    • 84858335459 scopus 로고    scopus 로고
    • One hundred years of allergen immunotherapy European academy of allergy and clinical immunology celebration: Review of unanswered questions
    • EAACI 100 Years of Immunotherapy Experts Panel.
    • Calderon M, Cardona V, Demoly P, EAACI 100 Years of Immunotherapy Experts Panel. One hundred years of allergen immunotherapy European academy of allergy and clinical immunology celebration: review of unanswered questions. Allergy 2012; 67: 462-476.
    • (2012) Allergy , vol.67 , pp. 462-476
    • Calderon, M.1    Cardona, V.2    Demoly, P.3
  • 14
    • 70449108193 scopus 로고    scopus 로고
    • Committee for Medicinal Products for Human Use CHMP/EWP/18504/2006. London. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. 20 November 2008. Available at Last accessed 20 March 2013
    • Committee for Medicinal Products for Human Use. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London. European Medicines Agency. Pre-authorisation evaluation of medicines for human use. 20 November 2008. Available at http://www.emea.europa.eu/docs/en-GB/document-library/Scientific- guideline/2009/09/WC500003605.pdf. Last accessed 20 March 2013
    • Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases
  • 15
    • 0345424863 scopus 로고    scopus 로고
    • Allergic rhinitis: clinical development programs for drug products Beltsville, MD, April 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at Last accessed 20 March 2013
    • Allergic rhinitis: clinical development programs for drug products. Guidance for Industry. Beltsville, MD, April 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm071293.pdf. Last accessed 20 March 2013.
    • Guidance for Industry
  • 16
    • 84880319526 scopus 로고    scopus 로고
    • Guidance for reviewers Beltsville, MD, November 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at Last accessed 20 March 2013
    • Guidance for reviewers. Potency limits for standardized dust mite and grass allergen vaccines: a revised protocol. Beltsville, MD, November 2000. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at http://www.fda.gov/OHRMS/DOCKETS/98fr/000218gd.pdf. Last accessed 20 March 2013.
    • Potency Limits for Standardized Dust Mite and Grass Allergen Vaccines: A Revised Protocol
  • 17
    • 84862294949 scopus 로고    scopus 로고
    • Immunogenic targets for specific immunotherapy in multiple myeloma
    • Zhang L, Götz M, Hofmann S, Greiner J,. Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol. 2012; 2012: 820394.
    • (2012) Clin Dev Immunol , vol.2012 , pp. 820394
    • Zhang, L.1    Götz, M.2    Hofmann, S.3    Greiner, J.4
  • 18
    • 2442536861 scopus 로고    scopus 로고
    • Specific immunotherapy in the U.S.A.: General concept and recent initiatives
    • Esch RE,. Specific immunotherapy in the U.S.A.: general concept and recent initiatives. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. 2003; 94: 17-23.
    • (2003) Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M. , vol.94 , pp. 17-23
    • Esch, R.E.1
  • 19
    • 79955409460 scopus 로고    scopus 로고
    • Allergen-specific immunotherapy: Current concepts and future directions
    • Bieber T, Simon HU,. Allergen-specific immunotherapy: current concepts and future directions. Allergy 2011; 66: 709-712.
    • (2011) Allergy , vol.66 , pp. 709-712
    • Bieber, T.1    Simon, H.U.2
  • 20
    • 79955473722 scopus 로고    scopus 로고
    • 100 years of hyposensitization: History of allergen-specific immunotherapy (ASIT)
    • Ring J, Gutermuth J,. 100 years of hyposensitization: history of allergen-specific immunotherapy (ASIT). Allergy 2011; 66: 713-724.
    • (2011) Allergy , vol.66 , pp. 713-724
    • Ring, J.1    Gutermuth, J.2
  • 21
    • 2342591290 scopus 로고    scopus 로고
    • A revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of World Allergy Organization
    • Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier B, Lockey R, et al. A revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of World Allergy Organization. J 7Allergy Clin Immunol 2004; 113: 832-836.
    • (2004) J 7Allergy Clin Immunol , vol.113 , pp. 832-836
    • Johansson, S.G.O.1    Bieber, T.2    Dahl, R.3    Friedmann, P.S.4    Lanier, B.5    Lockey, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.